Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
The use of single-chain variable fragment (scFv) constructs has been investigated in cancer radioimmunotherapy (RIT) and radioimmunodetection, as these molecules permit rapid tumor penetration and clearance from the serum relative to whole IgG. Multimerization of scFv constructs has demonstrated improvements in functional affinity (i.e., avidity) and maximal tumor uptake. In this paper, we report the first biodistribution and pharmacokinetics studies of a noncovalent, direct-linked scFv (V(L)-0-V(H)) trimeric/tetrameric "multimer" of the anti-Lewis Y monoclonal antibody, hu3S193. The in vitro binding and in vivo biodistribution of the hu3S193 multimer was characterized alongside the hu3S193 F(ab')(2) following radiolabeling with the Indium-111 ((111)In) radioisotope. Immunoreactivities of the radiolabeled multimer and F(ab')(2) were 73% and 53.2%, and binding affinities (K(a)) were 1.58 x 10(7) M(1) and 4.31 x 10(6) M (1) for the multimer and F(ab')(2), respectively. Maximal tumor uptake in Le(y)-positive MCF-7 breast cancer xenografted BALB/c nude mice was 12.6 +/- 2.5 percent injected dose/per gram (%ID/g) at 6 hours postinjection for the multimer and 15.7 +/- 2.1 %ID/g at 24 hours postinjection for the F(ab')(2). However, limited in vitro stability and high renal localization of radiolabeled constructs were observed, which, despite the observed tumor targeting of the hu3S193 multimer, most likely preclude its use in RIT and imaging modalities.
Kelly
Marcus P
MP
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia.
Lee
F-T
FT
Tahtis
Kiki
K
Power
Barbara E
BE
Smyth
Fiona E
FE
Brechbiel
Martin W
MW
Hudson
Peter J
PJ
Scott
Andrew M
AM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000235:genetics; D061067:Antibodies, Monoclonal, Humanized; D019540:Area Under Curve; D045744:Cell Line, Tumor; D002850:Chromatography, Gel; D004355:Drug Stability; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000097:blood / Q000493:pharmacokinetics*; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D007205:Indium Radioisotopes; D007983:Lewis Blood Group Antigens / Q000276:immunology*; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology / Q000378:metabolism*; D011877:Radionuclide Imaging; D011994:Recombinant Proteins / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C522039:Hu3S193 monoclonal antibody; D018796:Immunoconjugates; D007140:Immunoglobulin Fab Fragments; D007135:Immunoglobulin Variable Region; D007205:Indium Radioisotopes; D007983:Lewis Blood Group Antigens; C094162:Lewis Y antigen; D011994:Recombinant Proteins
Clin Cancer Res. 2001 Jan;7(1):175-84
11205906
Nat Rev Immunol. 2006 May;6(5):343-57
16622479
Protein Sci. 1997 Apr;6(4):781-8
9098887
Cancer Res. 1996 May 1;56(9):2123-9
8616860
J Nucl Med. 2006 Apr;47(4):716-25
16595507
Mol Cancer Ther. 2006 Jun;5(6):1550-8
16818514
J Nucl Med. 1993 Oct;34(10):1728-38
8410290
J Immunol Methods. 2001 Feb 1;248(1-2):47-66
11223068
Curr Opin Struct Biol. 1998 Aug;8(4):443-50
9729735
Protein Eng Des Sel. 2004 Jan;17(1):21-7
14985534
Nat Biotechnol. 2003 Dec;21(12):1486-92
14634668
Nucl Med Biol. 1995 Apr;22(3):387-90
7627155
Int J Cancer. 1997 Sep 26;73(1):50-6
9334809
J Mol Biol. 2005 Apr 8;347(4):773-89
15769469
J Nucl Med. 2005 Jan;46 Suppl 1:115S-27S
15653660
J Mol Biol. 1997 Apr 25;268(1):107-17
9149145
Bioorg Med Chem. 1997 Oct;5(10):1925-34
9370037
J Immunol Methods. 2000 Aug 28;242(1-2):193-204
10986400
Cancer Res. 1999 Jan 1;59(1):128-34
9892197
Int J Cancer. 1997 Jul 29;72(3):522-9
9247299
Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):657-70
16828920
Cancer Res. 2000 Jun 15;60(12):3254-61
10866319
Nat Biotechnol. 2005 Sep;23(9):1126-36
16151406
Nat Biotechnol. 2005 Sep;23(9):1137-46
16151407
Int J Cancer. 2004 Nov 10;112(3):509-18
15382079
Cancer Res. 1995 Sep 1;55(17):3825-34
7641200
Nat Med. 2003 Jan;9(1):129-34
12514726
Nucl Med Biol. 2005 Feb;32(2):157-64
15721761
Int Immunopharmacol. 2006 May;6(5):791-9
16546710
Clin Cancer Res. 2007 Jun 1;13(11):3286-92
17545534
Nucl Med Biol. 1995 May;22(4):413-23
7550017
Protein Eng Des Sel. 2004 Apr;17(4):357-66
15126676
Cancer Res. 2000 Dec 15;60(24):6964-71
11156397
Clin Cancer Res. 2001 Apr;7(4):1061-72
11309358
J Immunol Methods. 2004 Jun;289(1-2):65-80
15251413
Clin Cancer Res. 2005 Jul 1;11(13):4810-7
16000578
Cancer Treat Res. 1990;51:153-71
1977442
J Nucl Med. 2005 Jun;46(6):1012-5
15937313
Protein Sci. 2003 Apr;12(4):734-47
12649432
Biomol Eng. 2001 Oct 15;18(3):95-108
11566601
Biochem Biophys Res Commun. 2005 Feb 25;327(4):999-1005
15652494
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7109s-7121s
16203810
Clin Cancer Res. 1999 Oct;5(10 Suppl):3048s-3055s
10541342
J Immunol Methods. 1999 Dec 10;231(1-2):249-60
10648942
Curr Opin Biotechnol. 2002 Dec;13(6):603-8
12482521
J Nucl Med. 2001 Oct;42(10):1519-27
11585867
Q J Nucl Med Mol Imaging. 2004 Dec;48(4):279-88
15640791
Cancer Res. 2000 Sep 1;60(17):4804-11
10987290
Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):264-73
15791435